Categories Uncategorized

4 Considerations When Developing Mobile Health Devices

Modern-day mobile technology is making strides in the medical device industry and is opening up new avenues for both physicians and patients. However, for these devices to be successful, they need approval from the FDA. Initially, mobile technology was only referred to as the device that was implanted into patients and communicated directly to clinicians within the hospital’s confines.

This has now changed, and the trend is “wearables.” The wearable can be directly worn on the body or clothing as accessories. Currently, the wearables are being used mostly by athletes to monitor heart rates and other parameters. Your devices need to be approved for medical use, and here are the facts that you must consider to get this approval:

The FDA Must Clear the mHealth Apps

Mobile applications have become more common for people who are seeking to improve their overall health. These apps are used by consumers to track their daily calories, exercise, and other vital signs. Some of these consumer wearables are not medical devices and should not be considered products that can diagnose and treat. Furthermore, they cannot restore the health of an individual who has been impaired by infections.

Must Have Reliable Data

A suitable mobile device must empower physicians with reliable data and the physicians should be able to extract vital patient’s information from the device. Moreover, a first medical device should allow medics to monitor timings of dosages and frequency in a simpler way in form of charts and graphs.

The data should also be available to physicians from any place at the swipe of their fingers to determine possible treatment. Health data is very crucial in analyzing, treating, and caring for the patient. It is therefore critical for the FDA to validate the accuracy of the data.

Failure in the Software can Create Big Frustrations

The integration of software to control medical devices has evolved with the evolution of new technology. On the other hand, software failures have become the most significant cause of medical device recalls by the FDA. It is, therefore, necessary for medical device manufacturers to ensure effectiveness in medical software. Good software should be reliable and safe for medical use.

The Manufacturing Process of your Device is Essential to the FDA

The fruitful submission of your mHealth device to the FDA will depend on not only the accuracy of your data but also the reliability of the software. Therefore, your device needs to go through thorough validation, verification, and proper documentation by the FDA. Successful inspection from the FDA will confirm the safety and reliability of your medical equipment.

As mobile medical devices start playing a major role in the delivery of healthcare, the high stakes involved aren’t lost on biomedical firms like Genprex Inc. (NASDAQ: GNPX).

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation

Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs.…

3 days ago

Oncolytic Virus Therapy is Set to Transform Cancer Care

Enormous resources are being channeled into studying different ways to support the immune system in its fight…

3 days ago

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape

Recent research shows how chemotherapy and immunotherapy can complement each other when used together. Within…

3 days ago

Study Finds That Marijuana Legalization Lowers Crime Rates

David Eby, the Premier of British Columbia, has revealed that a wide range of American healthcare workers,…

4 days ago

Earth Science Tech Inc. (ETST) Builds Telehealth, Pharmacy Links in Evolving Digital Care

Patients increasingly prefer access, speed and convenience, but healthcare systems also need better coordination, safer…

5 days ago

Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Innovation Through Platform Science and Expanding Therapeutic Pipeline

High-quality development platforms and translational research frameworks have become essential tools in rare-disease biotechnology. Soligenix…

5 days ago